



**THE FOUNDATION
FOR SECURE
MARKETS**

#50549

Date: June 07, 2022

Subject: Ortho Clinical Diagnostics Holdings plc - Cash In Lieu Settlement
Adjusted Option Symbol: QDEL1

Ortho Clinical Diagnostics Holdings plc options were adjusted on May 27, 2022 (See OCC Information Memo #50499). The new deliverable became 1) 10 QuidelOrtho Corporation (QDEL) Common Shares, 2) Cash in lieu of 0.55 fractional QDEL Common Shares, and 3) \$714.00 Cash. Only settlement of the cash portion of QDEL1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of \$88.44 per whole QDEL share will be used to determine the cash in lieu amount. Accordingly, the cash in lieu amount is:

$$0.55 \times \$88.44 = \$48.64 \text{ per QDEL1 Contract}$$

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of May 27, 2022 through June 07, 2022, to deliver the appropriate cash amount.

The cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

Terms of the QDEL1 options are as follows:

New Deliverable

Per Contract: 1) 10 QuidelOrtho Corporation (QDEL) Common Shares
2) \$762.64 Cash (\$714.00 + \$48.64)

Strike Prices: Unchanged

CUSIP: QDEL: 219798105

Multiplier: 100 (i.e., a premium of 1.50 yields \$150)

Settlement

The QDEL component of QDEL1 exercise/assignment activity from May 27, 2022 through June 6, 2022, has settled through National Security Clearing Corporation (NSCC). The \$762.64 cash amount will be settled by OCC.

Pricing

The underlying price for QDEL1 will be determined as follows:

$$\text{QDEL1} = 0.10 (\text{QDEL}) + 7.6264$$

For example, if QDEL closes at 95.70, the QDEL1 price would be calculated as follows:

$$\text{QDEL1} = 0.10 (95.70) + 7.6264 = 17.20$$

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.